Table 2 Immune-related adverse events (Grade 2–4)

1.0 Skin toxicities

 Rash/Dermatitis

18 (13.0)

17 (12.3)

1 (0.7)

0 (0)

2.0 Gastrointestinal toxicities

 Colitis

17 (12.3)

11 (8.0)

6 (4.3)

0 (0)

 Hepatitis

17 (12.3)

8 (5.8)

7 (5.1)

2 (1.4)

3.0 Lung toxicities

 Pneumonitis

29 (21.0)

21 (15.2)

8 (5.8)

0 (0)

4.0 Endocrine toxicities

 Hyperthyroidism

35 (25.4)

33 (23.9)

2 (1.4)

0 (0)

 Adrenal insufficiency

3 (2.2)

3 (2.2)

0 (0)

0 (0)

 Pituitary hypophystis

16 (11.6)

12 (8.7)

4 (2.9)

0 (0)

 Diabetes

2 (1.4)

0 (0)

1 (0.7)

1 (0.7)

5.0 Musculoskeletal toxicities

 Arthritis

1 (0.7)

1 (0.7)

0 (0)

0 (0)

 Myositis

1 (0.7)

1 (0.7)

0 (0)

0 (0)

6.0 Renal toxicities

0 (0)

0 (0)

0 (0)

0 (0)

7.0 Nervous system toxities

 Optic neuritis

2 (1.4)

2 (1.4)

0 (0)

0 (0)

8.0 Hematologic toxicities

 Autoimmune hemolytic anemia

3 (2.2)

0 (0)

3 (2.2)

0 (0)

 Lymphopenia

1 (0.7)

0 (0)

1 (0.7)

0 (0)

9.0 Cardiovascular toxicities

 Myocarditis

1 (0.7)

0 (0)

0 (0)

1 (0.7)

 Vasculitis

1 (0.7)

0 (0)

1 (0.7)

0 (0)

 Pericardial effusion

2 (1.4)

0 (0)

2 (1.4)

0 (0)

 Arrhythmia

5 (3.6)

0 (0)

4 (2.9)

1 (0.7)

 Angina pectoris

3 (2.2)

0 (0)

2 (1.4)

1 (0.7)

 Heart failure

1 (0.7)

0 (0)

0 (0)

1 (0.7)

 Pulmonary embolism

1 (0.7)

0 (0)

0 (0)

1 (0.7)

10.0 Ocular toxicities

0 (0)

0 (0)

0 (0)

0 (0)